Kornimate/medical-research-clean huggingface dataset:
change history and adopt a robotic solution for angioplasty procedure

Conditions: Coronary Disease

Summary: the main objective of the change registry is the evaluation of the real-world performance and safety profile of the r-one system in pci.

the r-one system is a class "iib" ce marked medical device designed to remote deliver and manipulate coronary guidewires and stent/balloon devices during percutaneous coronary intervention (pci). the system comprises the r-one robotic platform used in combination with two accessories, the mobile radioprotection screen and a sterile and single-use r-one consumable kit. the r-one is not autonomous and operates only under the operator's commands. this study is a single-arm, open-label, multi-center registry. the change registry, part of the robocath's post-market clinical follow-up activities, is a real world study aiming to confirm the safety and performance, including the clinical benefit, of the r-one robotic systems medical device. 500 patients with coronary artery disease and with clinical indication for pci will be recruited in up to up to 15 centers distributed in europe and south africa.

Eligibility criteria:
inclusion criteria: * 1. age ≥ 18 years; * 2.subjects with coronary artery disease with clinical indication for pci; * 3.subject deemed appropriate for robotic-assisted pci; and * 4.the subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. exclusion criteria: * 1.failure/inability/unwillingness to provide informed consent, unless the ethic committee has waived informed consent; or * 2.the investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted pci. * 3.stemi * 4.cardiogenic shock * 5.subjects will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.
comparative study of different i-131 doses in graves' disease

Conditions: Graves' Disease

Summary: radioactive iodine (rai) administration is an effective and completely established treatment modality in hyperthyroidism including graves' disease. despite the long experience with radioiodine for hyperthyroidism, controversy remains regarding the optimal dose of iodine that is required to achieve long-term euthyroidism. the fixed activity administration method does not optimize the therapy, giving often too high or too low radiation to the gland, but the optimal dose per gram of thyroid mass in calculated activity administration method is also under much debates. this prospective study has been designed in order to compare the effect of different calculated doses of radioiodine on graves' disease treatment outcome.


Eligibility criteria:
inclusion criteria: * age 18-65 hyperthyroid patients (graves'disease) exclusion criteria: * pregnancy or lactation

Keywords: radioiodine therapy graves' disease hyperthyroidism calculated dose
evaluation of the rate of consultations in gynecological emergencies under "non-urgent" management

Conditions: Gynecologic Disease

Summary: the difference between the demand and the current medical supply poses a real public health problem in terms of the organization of health care systems. for several years in france, there has been an increase in the number of consultations in emergency services, particularly gynaecological ones. the two causes put forward are a change in user behavior with an increase in requests for rapid but "non-urgent" care and the inadequacy of the supply of care in the private sector. few studies have been carried out concerning gynaecological emergencies, unlike general emergencies. the aim of this study is to measure the frequency of consultations in gynaecological emergencies for non-emergency reasons. the interest of this study is therefore mainly on the optimization of the care system with the emphasis on the city-hospital network in the management of these patients.


Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * patient not pregnant or pregnant \< 14 sa * patient admitted for gynecological emergency care at paris saint-joseph hospital between 01/02/2021 and 30/04/2021 * french-speaking patient exclusion criteria: * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patient objecting to the use of her data for this research
impact of disease modifying therapies (dmts) and associated support services in relapsing multiple sclerosis (rms) patients

Conditions: Relapsing Multiple Sclerosis

Summary: the objective is to establish the impact of current disease modifying therapies (dmts) and associated support services on patient reported experience measures and patient reported outcomes in relation to the treatment and management of relapsing multiple sclerosis in the united kingdom (uk).


Eligibility criteria:
inclusion criteria: * relapsing multiple sclerosis patients aged 18 years or over. * naive to previous dmt therapy and not yet started treatment with a disease modifying therapy. exclusion criteria: * participating in an ms-related clinical trial. * unwilling to provide electronic online consent. * any disability that may impair them from being able to complete the online questionnaire. * do not have regular access to the internet. * unable to complete the baseline questionnaire before they receive their first dmt injection.

Keywords: multiple sclerosis patient reported outcome patient reported experience
effects of probiotic supplementation with weight reducing plan in patients with food addiction and weight regain after bariatric surgery

Conditions: Weight Regain After Bariatric Surgery and Food Addiction

Summary: to study the effects of probiotic supplementation with a weight loss program and cognitive behavioral therapy (cbt) on anthropometric measures, eating behavior, food addiction, and related hormone levels in patients with food addiction and weight regain after bariatric surgery, 50 patients who referred to obesity clinic with weight regain (regaining ≥10% nadir weight) after bariatric surgery (at least 18 months), and food addiction will be randomly allocated to receive a weight loss program and cbt plus either probiotic, or placebo for 12 weeks. at the first and the end of the intervention, anthropometric measurements, eating behavior, food addiction, leptin, serotonin, and oxytocin will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: * bmi ≥25 kg/m2; willingness to participate in the study; not having diseases such as cancer, thyroid, diabetes, renal or liver (except fatty liver); non-pregnant or lactating or menopause or professional athlete; not use of any antibiotics in the last three weeks and any protein or probiotic supplement in the last month exclusion criteria: * taking antibiotic; using probiotic supplements/products or protein supplements; using weight-loss or appetite-suppressing medications; pregnancy; consuming less than 90% of the supplements prescribed during the study; following less than 90% of diet or physical activity for more than 10 days; participants who refuse to continue the study
fusion imaging contrast-enhanced ultrasound li-rads

Conditions: Hepatocellular Carcinoma

Summary: ceus li-rasd apply to lesion visible at precontrast ultrasound but not the lesion invisible. fusion imaging can use to invisible lesions at precontrast ultrasound in clinical practice. thus, our aim is to explore the application value of ceus li-rads in contrast-enhanced fusion imaging for focal liver lesions that are not visible on conventional ultrasound in high-risk patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: patients at risk for hcc(cirrhosis or chronic hepatitis b viral infection or current or prior hcc) suspicious lesions detected by cect/mri but not visible on conventional ultrasound and us-cect/mri fusion imaging patients sign the informed consent. exclusion criteria: patients without risk of hcc(with cirrhosis due to congenital hepatic fibrosis or with cirrhosis due to a vascular disorder such as hereditary hemorrhagic telangiectasia, budd-chiari syndrome, chronic portal vein occlusion, cardiac congestion, or diffuse nodular regenerative hyperplasia) patients without a successful registration or lesions can be seen on conventional ultrasound after successful registration pregnancy or lactation patients with pretreat lesion patients don't sign the informed consent.
skin, muscle and bone aging determinants in hiv infected-patients.

Conditions: HIV-1-infection; Marker; Structural

Summary: this study consists of the study of markers of skin, muscular, neurocognitive and bone aging in hiv infected adults and to compare the frequency of these signs to the general population of same gender and age.

nowadays, the elevated frequency of cancers as well as cardiovascular, neurocognitive and bone diseases seems to denote a process of accelerated aging in the treated hiv-infected population of western countries, who are 40 to 50 years old in median. markers of age-related alterations should be compared to the distribution among the general population whenever possible, to disentangle the effect of hiv and "normal" ageing or ageing due to other conditions. common mechanisms should be better understood, more specifically those related to the impact of tobacco, antiretroviral treatments, and nutritional components. for markers of skin, muscle, neurocognitive function and bone ageing, the distribution of the general population is available and, in addition, alteration of these markers might have common mechanisms, such as insufficiency in 25 hydroxy vitamin d or nutritional parameters. therefore, a joint study of these three organs seems particularly relevant. this aim is to study markers of skin, muscular, neurocognitive and bone aging in hiv infected adults and to compare the frequency of these signs to the general population of same gender and age.

Eligibility criteria:
inclusion criteria: * hiv-1 infected patients included in the tissos-vih substudy of the arns co3 aquitaine cohort or who had a dxa measurement of the lumbar spine, femoral neck, and total body between 2004 and 2011 at the university hospital of bordeaux, * \> 18 years * affiliated to the medical insurance * having had at least one dxa measurement prior to the simbad study visit * written informed consent for the simbad study exclusion criteria: * hepatitis c virus co-infection * pregnancy

Keywords: alterations
octenidine and sodium hypochlorite for pulp irrigation in direct pulp capping

Conditions: Pulp Exposure, Dental

Summary: in the included patients, after complete removal of caries from the entire cavity, the exposed pulp will be treated with either a 2.5% naocl or 0.1% octenidine solution. subsequently, the cavity will be restored using calcium silicate cement, glass ionomer cement, and composite resin. postoperatively, the patient's pain level will be assessed using the visual analogue scale (vas) at 24 and 72 hours, as well as on the 7th day. responses to pulp sensitivity tests and periapical radiographs will be evaluated at 6 months.

after obtaining a detailed pain history from the patients and conducting clinical and radiographic examinations, if a case is deemed suitable for the study, patients will be informed about the possibility of participating in this research project and the procedures involved. the risks and benefits associated with the study will be explained to the patients. once a patient is considered a potential candidate for the study and expresses interest in participation, informed consent will be obtained. before the caries removal procedure, local anesthesia will be administered, and the teeth will be isolated using a rubber dam. cavities will be prepared using a diamond bur under continuous water cooling. caries will be completely removed from the entire cavity with the help of steel round burs and excavators, continuing until hard dentin is reached. bleeding from the exposed pulp will be controlled by pressing a cotton pellet soaked in sterile physiological saline onto the exposure site for one minute. at this point, a researcher not involved in this study will provide the treating clinician with a glass dish containing either a 2.5% naocl or 0.1% octenidine solution. a cotton pellet soaked in the test or control solution will be applied to the exposed pulp, and the cavity will be gently wiped. the cavity will be restored using calcium silicate cement, glass ionomer cement, and composite resin. postoperatively, the patient's pain levels will be assessed using the visual analogue scale (vas) at 24 and 72 hours, as well as on the 7th day. pulp sensitivity tests and periapical radiographs will be conducted at 6 months to evaluate the outcome.

Eligibility criteria:
inclusion criteria: * asymptomatic posterior tooth (premolar or molar) with deep caries * a healthy periodontal status, normal probing depth, and restorable. * negative responses to percussion and palpation tests while responding positively to cold testing and electric pulp testing exclusion criteria: * participants will be excluded if they had any systemic diseases * a negative response to cold testing and electric pulp testing. * presence of a sinus tract, absence of pulp exposure following complete caries removal, or necrotic or partially necrotic pulp tissue

Keywords: pulp exposure calcium silicate cement
an exploratory investigation of a cbd supplement's impact on sleep, stress, and focus

Conditions: Anxiety; Fear; Stress; Low Mood; Sleep

Summary: a high-quality broad-spectrum cannabidiol supplement with a bio-terpene complex will be administered once daily. it is hypothesized that this supplement will lead to improvements in sleep, focus, and stress. previous research supports that cbd supplementation provides support to the endocannabinoid system, allowing the brain to better control negative psychological outcomes like fear, stress, and negative mood states.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * ability to take oral medication and be willing to adhere to the dietary supplement regimen (1 capsules per day). * must be in general good health (e.g., no long term health issues that would impact your participation. * moderate self-reported issues with stress, mood, focus, and sleep. exclusion criteria: * current use of selective serotonin reuptake inhibitors or prescription medication for the treatment of depression or anxiety and have not been on a stable dose for more than 60 days. * currently receiving other psychotherapeutic treatment for anxiety or depression. * diagnosed anxiety or depression * bmi over 40 * known allergic reactions that would require the use of an epi-pen * females who are pregnant or breastfeeding.

Keywords: anxiety fear stress low mood sleep focus calmness
a long term follow-up study of patients from the rep 301 protocol

Conditions: Hepatitis B, Chronic; Hepatitis D, Chronic

Summary: the rep 301 treatment protocol involved the treatment of patients with chronic hepatitis b / hepatitis d co-infection with two agents: rep 2139-ca and pegylated interferon (peg-ifn). in this protocol, similar reduction/clearance of serum hbsag and improved response to immunotherapy were observed in addition to clearance of serum hdv rna. the rep 301 protocol was designed to include a 24 week follow-up period after treatment, however given the strong antiviral response against hbv and hdv infection in these patients, it is now important to extend the follow-up period in these patients to monitor over a longer period after treatment the safety and efficacy combined rep 2139-ca / peg-ifn treatment in patients in the rep 301 protocol.

the rep 301-ltf is a long-term follow-up, non-blinded study of patients from the rep 301 protocol. in this study, all eligible patients from the rep 301 protocol will have their followup evaluation extended for an additional 3 years, consisting of 6 visits scheduled every 6 months following the last follow-up visit scheduled in the rep 301 protocol. during each visit a physical examination and documentation of any symptoms, experiences will be conducted as well as blood tests for safety and virology as described below. this study will examine the long term safety effects in patients who have completed of treatment exposure in the rep 301 trial (rep 2139-ca therapy for 30 weeks and peg-ifn taken for 48 weeks with a 15 week overlap in combination) and the duration of suppression of serum hbv and hdv viremia observed in the rep 301 protocol. this requires that subjects have completed antiviral treatment in the rep 301 protocol and are not immediately transitioned to further antiviral treatment unless necessary. the total duration of this study for each subject is 3 years.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent. exclusion criteria: 1. any patients not enrolled in the rep 301 protocol or not successfully completing all treatment and follow-up visits in the rep 301 protocol 2. a history of alcohol abuse within the last year 3. the use of illicit drugs within the past two years. 4. inability to provide informed consent. 5. inability or unwillingness to provide blood samples.

Keywords: nucleic acid polymer rep 2139 hbsag hepatitis b hepatitis d
a study of s5g4t-1 in the treatment of papularpustular rosacea

Conditions: Papulopustular Rosacea

Summary: to assess the efficacy and safety of s5g4t-1 compared to s5g4t-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

in this phase 3, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met. male and female participants at least 18 years of age with moderate or severe papulopustular rosacea will be eligible for enrollment for daily treatment with s5g4t-1 or its vehicle for 12 weeks.

Eligibility criteria:
inclusion criteria: 1. participants must sign an institutional review board (irb) approved written informed consent for this study. 2. male and female 18 years of age and older. 3. participants must have clinical diagnosis of moderate to severe rosacea. 4. have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose. 5. have 2 nodules or less. exclusion criteria: 1. females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at baseline or screening visits. 2. presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm). 3. current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

Keywords: papulopustular rosacea
prediction of left ventricular adverse remodeling and major adverse cardiovascular events in patients with acute myocardial infarction though plasma multiomics analysis.

Conditions: Acute Myocardial Infarction (AMI); Left Ventricular Remodeling; Major Adverse Cardiovascular Event; Plasma Multi-Omics

Summary: to identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (lvar) and major adverse cardiovascular events (mace) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to lvar and mace.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. diagnosis of ami (stemi or nstemi) confirmed by clinical criteria, electrocardiogram (ecg), and cardiac biomarkers (e.g., troponin). 3. willingness to provide informed consent. exclusion criteria: 1. prior surgery or trauma. 2. renal failure with glomerular filtration \<30 ml/min.
effects of botulinum toxin injection combined with reswt in lower extremity spasticity in children with cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: this study aimed to check and compare the effects of botulinum toxin injection combined with shock wave therapy versus botulinum toxin injection only for lower extremity spasticity in children with cerebral palsy

20 pediatric patients diagnosed with cerebral palsy who received botulinum toxin type a injection for lower extremity spasticity were divided into two groups. the first group will receive only conventional treatment after the injection, while the second group will receive extracorporeal shockwave therapy for injected muscles. the shock wave therapy is planned as 3 sessions per week, starting one week after the injection. patients will be compared in terms of mas scores, mts scores, passive joint range of motion, modified timed up and go test, pain scores, (faces pain scale-revised) and goal attainment scaling scores. patients will be evaluated 1 week, 1 month and 3 months after the injection with pre-injection data.

Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy. * spasticity in at least one of the lower extremity muscle groups. * no contraindications to shockwave therapy. * applied botulinum toxin type a injection for at least one spastic muscle of lower extremity. * agreed to participate to study (patient/primary caregiver) exclusion criteria: * surgery history within the last year of the muscle to be injected and treated * having uncontrolled epilepsy. * having infection * coagulopathy

Keywords: cerebral palsy spasticity botulinum toxin injection extracorporeal shockwave therapy
mini-flap baba (bilateral axillo-breast approach) robotic thyroidectomy is safe

Conditions: Thyroid Nodule

Summary: in this study, a randomized controlled study was conducted between two groups of 40 recipients of conventional flap during baba robotic-thyroidectomy and 40 recipients of mini-flap method during baba robotic-thyroidectomy. in this study, we tried to determine whether the use of mini-flap can reduce sensory loss and pain after baba robotic-thyroidectomy.


Eligibility criteria:
inclusion criteria: * subjects who will have thyroid surgery * subjects who has no evidence of lymph node metastasis on palpation and imaging (cn0) * subjects who has thyroid nodule under 4cm (\<ct2) * subjects who has no distant metastasis (m0) exclusion criteria: * subjects who has clinical evidence of lymph node metastasis (cn1a or cn1b) * subjects who has both thyroid nodule * subjects who underwent any radiotherapy on neck * subjects who has primary hyperparathyroidism * subjects who underwent head and neck surgery * subjects who disagree to do this trial

Keywords: mini-flap bilateral axillo-breast approach da vinci robot-assisted thyroid surgery